Outcome MeasureWell-being

GAF

Global Assessment of Functioning

7 Papers in Blossom

About This Instrument

The Global Assessment of Functioning (GAF) is a clinician-rated numeric scale (0–100) used to assess the overall social, occupational, and psychological functioning of an individual. It was introduced as Axis V of the DSM-IV multiaxial system. Higher scores reflect better functioning: 91–100 indicates superior functioning with no symptoms, while scores below 30 reflect serious impairment including inability to function in almost all areas. Although the GAF was removed from DSM-5 in favor of the WHODAS 2.0, it remains widely used in psychedelic research as a measure of global clinical improvement. The GAF is valued for its simplicity and ability to capture overall treatment response in a single number, though it has been criticized for conflating symptom severity with functional impairment.

Clinical Thresholds

0100
Severe impairment
Score 030
Major impairment
Score 3150
Moderate symptoms
Score 5160
Mild symptoms
Score 6170
Good functioning
Score 7190
Superior
Score 91100

Outcome Data Across Studies

Reported results for GAF across 6 studies with quantitative data.

Outcome data across 17 study arm–timepoint observations
SD
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
2016Secondary
Psilocybin(experimental)01250.39.2
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
2016Secondary
Psilocybin(experimental)71277.713.0
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial
2018Secondary
Full dose(experimental)0345.0
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial
2018Secondary
Full dose(experimental)60371.7
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study
2020Secondary
MDMA-assisted therapy(experimental)01368.55.4
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study
2020Secondary
MDMA-assisted therapy(experimental)301375.19.9
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study
2020Secondary
Placebo with therapy(inactive)0569.813.4
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study
2020Secondary
Placebo with therapy(inactive)30572.87.7
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil
2021Secondary
MDMA-assisted psychotherapy(experimental)0345.00.0
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil
2021Secondary
MDMA-assisted psychotherapy(experimental)112371.715.3

Papers Using GAF

Quick Facts

Full Name
Global Assessment of Functioning
Domain
Well-being
Papers Indexed
7
Score Range
0100
Interpretation
Higher = better
Unit
points
All Measures